This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NextGen's Medfusion Buyout to Improve Patient Experience
by Zacks Equity Research
NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.
Dentsply International (XRAY) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 14.00% and 1.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
XRAY or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. WST: Which Stock Is the Better Value Option?
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
Can All-Line Growth Boost CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
The newly-incorporated Health Care Benefits business already registers top-line contributions for CVS Health (CVS).
Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
by Zacks Equity Research
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.
Why Dentsply (XRAY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in the Cards for Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
In Spine & CMF, Zimmer Biomet (ZBH) is witnessing slowdown in growth due to difficult comps.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
by Zacks Equity Research
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
What's in the Offing for LabCorp's (LH) Earnings in Q3?
by Zacks Equity Research
LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.
Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?
by Zacks Equity Research
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).
What's in Store for Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.